Prednisone Intensol (prednisone)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Prednisone is a synthetic glucocorticoid.
Prednisone is usually considered the oral glucocorticoid of choice for anti-inflammatory or immunosuppressant effects. Because it has only minimal mineralocorticoid properties, the drug is inadequate alone for the management of adrenocortical insufficiency. If prednisone is used in the treatment of this condition, concomitant therapy with a mineralocorticoid is also required.
Generic name: prednisone
Pronunciation: (PRED-ni-sone)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Prednisone Intensol
Indications
The following indications are listed for Prednisone Intensol:
- Acquired Thrombocytopenia
- Acute Exacerbation Of Multiple Sclerosis
- Acute Gouty Arthritis
- Acute Lymphoid Leukemia
- Acute Rheumatic Carditis
- Adrenocortical Insufficiency
- Adrenogenital Disorder
- Allergic Bronchopulmonary Aspergillosis
- Allergic Rhinitis
- Ankylosing Spondylitis
- Aspiration Pneumonitis
- Asthma Exacerbation
- Atopic Dermatitis
- Autoimmune Hemolytic Anemia
- Berylliosis
- Bronchiolitis Obliterans With Organizing Pneumonia
- Cerebral Edema
- Chronic Lymphoid Leukemia
- Congenital Adrenal Hyperplasia
- Contact Dermatitis
- Crohn's Disease
- Cutaneous T-Cell Lymphoma
- Dermatitis Herpetiformis
- Diamond Blackfan Anemia
- Diffuse Large B-Cell Lymphoma
- Diffuse Proliferative Lupus Nephritis
- Epicondylitis
- Erythema Multiforme
- Erythroblastic Anemia
- Exacerbation Of Chronic Obstructive Pulmonary Disease
- Exfoliative Dermatitis
- Follicular Lymphoma
- Hodgkin's Lymphoma
- Humoral Hypercalcemia Of Malignancy
- Hypersensitivity Drug Reaction
- Hypersensitivity Pneumonitis
- Idiopathic Pulmonary Fibrosis
- Idiopathic Thrombocytopenic Purpura
- Inflammatory Bowel Disease
- Juvenile Idiopathic Arthritis
- Loffler Syndrome
- Mycosis Fungoides
- Nephrotic Syndrome
- Non-Hodgkin's Lymphoma
- Ophthalmia Sympathetic
- Organ Transplant Rejection
- Pemphigus
- Pneumocystis Jirovecii Pneumonia
- Polymyalgia Rheumatica
- Primary Adrenocortical Insufficiency
- Psoriasis
- Psoriatic Arthritis
- Pulmonary Tuberculosis
- Pure Red Cell Aplasia Associated With Chronic Lymphocytic Leukemia
- Relapsing Polychondritis
- Rheumatoid Arthritis
- Sarcoidosis
- Serum Sickness
- Severe Persistent Asthma
- Sjogren's Syndrome
- Systemic Dermatomyositis
- Systemic Lupus Erythematosus
- Thyroiditis
- Trichinosis
- Tuberculosis Meningitis Treatment Adjunct
- Ulcerative Colitis
- Uveitis
- Vasculitis
Also known as: Aase Syndrome, Acquired Hemolytic Anemia Due To Antibodies, Acute Articular Gout, Acute Exacerbation Of Ms, Acute Gout Attack, Acute Gout Flare, Acute Lymphatic Leukemia, Acute Lymphocytic Leukemia, Acute Lymphogenous Leukemia, Acute Relapse Of Ms, Acute Relapse Of Multiple Sclerosis, Acute Uratic Arthritis, Acutely Deteriorating Chronic Obstructive Pulmonary Disease, Addison Melanoderma, Adrenal Cortical Hypofunction, Adrenal Failure, Adrenal Insufficiency, Adrenocortical Hypofunction, Adrenogenital Syndrome, Aggravation Of Asthma, Allergic Alveolitis, Anemia Lymphatica, Angiitis, Arthritis Deformans, Arthrosis Deformans, Asthenia Pigmentosa, Atopic Eczema, Axial Spondyloarthritis With Radiographic Sacroiliitis, Bekhterev's Arthritis, Bekhterev's Disease, Bekhterev's Spondylitis, Besnier-Boeck-Schaumann Disease, Besnier-Boeck-Schaumann Syndrome, Blackfan Diamond Syndrome, Blistering Skin Disease, Boeck's Disease, Boeck's Sarcoid, Brain Edema, Bullous Dermatitis Herpetiformis, Chronic Adrenocortical Insufficiency, Chronic Atrophic Polychondritis, Colitis Ulcerativa, Congenital Erythroid Hypoplastic Anemia, Congenital Hypoplastic Anemia, Congenital Pure Red Cell Aplasia, Congenital Suprarenal Hyperplasia, Constitutional Erythroid Hypoplasia, Cryptogenic Fibrosing Alveolitis, Cryptogenic Organizing Pneumonia, Deficiency In Bone Marrow Erythroblasts, Dermatitis Venenata, Disseminated Lupus Erythematosus, Disseminated Neurodermatitis, Drug Hypersensitivity Reaction, Drug-Induced Hypersensitivity, Drug-Induced Hypersensitivity Reaction, Erythema Exfoliativa, Erythema Polymorphe, Erythroblastopenia, Erythroderma Exfoliativa, Erythrogenesis Imperfecta, Exacerbation Of Asthma, Exacerbation Of Copd, Exfoliative Eczema, Exfoliative Erythroderma, Extrinsic Allergic Alveolitis, Follicular B-Cell Lymphoma, Follicular B-Cell Non-Hodgkin's Lymphoma, Generalized Chondromalacia, Gougerot-Sjogren Disease, Hebra's Disease, Herpes Iris, Hodgkin's Disease, Hypercalcemia Associated With Cancer, Hypercalcemia Associated With Malignancy, Hypercalcemia Of Malignancy, Hypersensitivity Pneumonia, Hypoadrenalism, Hypocorticoidism, Idiopathic Fibrosing Alveolitis, Immune Thrombocytopenia, Immune Thrombocytopenia Purpura, Juvenile Ra, Juvenile Rheumatoid Arthritis, Loeffler Syndrome, Loffler's Syndrome, Lupus Erythematosus Syndrome, Lymphoblastic Leukemia, Malignant Hypercalcemia, Marie-Strumpell Disease, Marie-Strumpell Spondylitis, Melasma Addisonii, Mendelson's Syndrome, Meyenburg's Disease, Meyenburg-Altherr-Uehlinger Syndrome, Multiple Sclerosis Exacerbation, Nodose Rheumatism, Non-Hodgkin's Type Lymphoma, Organ Transplant Rejection Reaction, Pie Syndrome, Pneumocystis Jirovecii (Carinii) Pneumonia, Pneumocystis Pneumonia, Pneumocystosis Jirovecii Pneumonia, Post Infectious Thrombocytopenia, Prca Associated With Cll, Primary Adrenal Deficiency, Primary Adrenal Insufficiency, Primary Corticoadrenal Insufficiency, Primary Cutaneous T-Cell Lymphoma, Primary Failure Adrenocortical Insufficiency, Psoriasis Arthropica, Psoriatic Arthropathy, Pulmonary Pneumocystosis, Pulmonary Tb, Purpura Hemorrhagica, Regional Enteritis, Regional Ileocolitis, Relapsing Perichondritis, Rheumatic Arthritis, Rheumatic Gout, Rheumatoid Spondylitis, Rhizomelic Spondylitis, Rhizomelic Spondylosis, Schaumann's Syndrome, Secondary Thrombocytopenia, Serum Sickness-Like Reaction, Sicca Syndrome, Simple Pulmonary Eosinophilia, Sjogren's Disease, Small Cerebriform Cell Lymphoma, Spondylosis Deformans, Strumpell-Marie Disease, Suprarenal Failure, Sympathetic Ophthalmia, Systemic Chondromalacia, Transplant Rejection, Trichinella Spiralis Infection, Trichinellosis, Trichiniasis, Von Meyenburg's Disease, Werlhof's Disease.
Dosing
Dosage of prednisone depends on the condition being treated and the response of the patient. Dosage for infants and children should be based on the severity of the disease and the response of the patient rather than on strict adherence to dosage indicated by age, body weight, or body surface area. After a satisfactory response is obtained, dosage should be decreased in small decrements to the lowest level that maintains an adequate clinical response. The drug should be discontinued as soon as possible. Patients should be continually monitored for signs that indicate dosage adjustment is necessary, such as remissions or exacerbations of the disease and stress (surgery, infection, trauma). When long-term prednisone therapy is necessary, an alternate-day dosage regimen should be considered. Following long-term therapy, prednisone should be withdrawn gradually. (See the Corticosteroids General Statement 68:04.)
The initial adult dosage of prednisone may range from 5-60 mg daily, depending on the disease being treated, and is usually administered in 2-4 divided doses. Some clinicians state that children may be given a dosage of 0.14-2 mg/kg daily or 4-60 mg/m2 daily, administered in 4 divided doses.
Prednisone is administered orally. For patients unable to swallow tablets, prednisone may be administered orally as a commercially available solution, concentrate solution, or an extemporaneously prepared suspension. The oral concentrate may be diluted in juice or other flavored diluent or in semisolid food (e.g., applesauce) prior to administration.
An extemporaneous prednisone suspension containing 10 mg/mL can be prepared in the following manner. First, 5 g of prednisone as tablets is mixed with 200 mL of 0.1% sodium benzoate solution; 100 mL of an aqueous suspension containing 3% tragacanth, 3% acacia, and 0.1% sodium benzoate is then added, and the mixture is stirred until homogeneous. When the prednisone suspension is diluted to 500 mL with a mixture of 67% simple syrup and 33% cherry syrup, it contains prednisone 10 mg/mL and is apparently stable for 2 months at 2-8degreesC. (4 L of the tragacanth-acacia suspension may be prepared in a container that can be closed for vigorous agitation. Initially, 4 g of sodium benzoate is dissolved in 2 L of purified water. Then 120 g of powdered tragacanth and 120 g of acacia are added in that order and the container shaken vigorously. Additional water is added gradually over 24-48 hours with agitation at regular intervals until a volume of 4 L and a smooth suspension results. To mask the odor, 1 mL of anise oil may be added.)
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.